Abstract
Intravenous immunoglobulins (IVIg) have been shown in a number of trials, to be an effective treatment for the three main types of inflammatory neuropathies: Guillain-Barre Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). IVIg is thought to exert its immunomodulatory effects by affecting several components of the immune system including B-cells, T-cells, macrophages, complement, cytokines and cellular adhesion molecules. This article reviews the published evidence and the principal postulated mechanisms of action of intravenous immunoglobulins with special emphasis on inflammatory neuropathies.
Keywords: Intravenous immunoglobulins, mechanisms of action, inflammatory neuropathy, Guillain Barre syndrome, Chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy
Current Neuropharmacology
Title: Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies
Volume: 7 Issue: 4
Author(s): Saiju Jacob and Yusuf A. Rajabally
Affiliation:
Keywords: Intravenous immunoglobulins, mechanisms of action, inflammatory neuropathy, Guillain Barre syndrome, Chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy
Abstract: Intravenous immunoglobulins (IVIg) have been shown in a number of trials, to be an effective treatment for the three main types of inflammatory neuropathies: Guillain-Barre Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). IVIg is thought to exert its immunomodulatory effects by affecting several components of the immune system including B-cells, T-cells, macrophages, complement, cytokines and cellular adhesion molecules. This article reviews the published evidence and the principal postulated mechanisms of action of intravenous immunoglobulins with special emphasis on inflammatory neuropathies.
Export Options
About this article
Cite this article as:
Jacob Saiju and Rajabally A. Yusuf, Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies, Current Neuropharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157015909790031166
DOI https://dx.doi.org/10.2174/157015909790031166 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Editorial (Thematic Issue: Biologics in Autoimmune Diseases)
Current Pharmaceutical Biotechnology Tyrosine Kinases and Inflammatory Signalling
Current Molecular Medicine Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology TNF-induced Lupus. A Case-Based Review
Current Rheumatology Reviews Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Neural Stem Cell Transplantation and CNS Diseases
CNS & Neurological Disorders - Drug Targets Nitric Oxide-cGMP Signaling: Its Role in Cell Junction Dynamics During Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Review of the Treatment of Psoriasis with Infliximab
Reviews on Recent Clinical Trials Role of DAP12 in Innate and Adaptive Immune Responses
Current Pharmaceutical Design Modulation of Eosinophil Functions by Nitric Oxide: Cyclic GMPdependent and -independent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design Recent Patents Relating to Diagnostic Advances in Age Related Macular Degeneration (AMD)
Recent Patents on DNA & Gene Sequences Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology CT Findings of Pulmonary Metastases from Primary Cardiac Angiosarcoma
Current Medical Imaging Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Current Pharmaceutical Design The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology